Chicago Capital LLC Reduces Stock Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Chicago Capital LLC cut its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 0.7% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,602,073 shares of the biopharmaceutical company’s stock after selling 40,336 shares during the period. Dynavax Technologies makes up approximately 1.9% of Chicago Capital LLC’s holdings, making the stock its 19th largest holding. Chicago Capital LLC owned about 4.28% of Dynavax Technologies worth $62,911,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. New York State Common Retirement Fund boosted its stake in shares of Dynavax Technologies by 5.7% in the fourth quarter. New York State Common Retirement Fund now owns 52,725 shares of the biopharmaceutical company’s stock valued at $737,000 after purchasing an additional 2,860 shares during the period. Natixis Advisors L.P. grew its stake in shares of Dynavax Technologies by 10.5% during the fourth quarter. Natixis Advisors L.P. now owns 19,058 shares of the biopharmaceutical company’s stock valued at $266,000 after acquiring an additional 1,804 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Dynavax Technologies by 23.6% during the fourth quarter. BNP Paribas Financial Markets now owns 413,409 shares of the biopharmaceutical company’s stock worth $5,779,000 after acquiring an additional 78,824 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Dynavax Technologies by 7.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock worth $56,372,000 after acquiring an additional 293,337 shares in the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in Dynavax Technologies during the 4th quarter valued at approximately $1,746,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Stock Performance

Shares of NASDAQ DVAX traded up $0.18 during trading on Friday, reaching $11.03. The stock had a trading volume of 1,800,208 shares, compared to its average volume of 2,109,793. The firm’s 50 day moving average price is $11.01 and its two-hundred day moving average price is $11.60. Dynavax Technologies Co. has a one year low of $9.74 and a one year high of $15.15. The stock has a market cap of $1.44 billion, a PE ratio of 183.83 and a beta of 1.37. The company has a debt-to-equity ratio of 0.35, a quick ratio of 13.18 and a current ratio of 14.18.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.02. Dynavax Technologies had a net margin of 6.88% and a return on equity of 2.76%. The firm had revenue of $73.80 million during the quarter, compared to analyst estimates of $76.92 million. During the same quarter in the previous year, the firm earned $0.03 earnings per share. On average, research analysts forecast that Dynavax Technologies Co. will post 0.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on DVAX shares. The Goldman Sachs Group cut their target price on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research note on Wednesday, August 7th. Finally, StockNews.com downgraded shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Dynavax Technologies currently has an average rating of “Moderate Buy” and an average target price of $23.67.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.